MARC Affirms Sunway Healthcare AA Ratings On Its RM5 Billion Sukuk
MARC Affirms Sunway Healthcare AA Ratings On Its RM5 Billion Sukuk
MARC Ratings has affirmed its rating of AAIS(cg) on Sunway Healthcare Treasury Sdn Bhd's (SH Treasury) Islamic Medium-Term Notes (Sukuk Wakalah) Programme of up to RM5.0 billion with a Stable outloo.
MARC評級已確認對Sunway Healthcare Treasury Sdn Bhd(SH Treasury)的伊斯蘭中期票據(Sukuk Wakalah)計劃的AAIS(cg)評級,額度高達50億馬幣,前景穩定。
The agency said the rating reflects the credit strength of parent Sunway Healthcare Holdings Sdn Bhd (SHH), based on SHH's unconditional and irrevocable guarantee on the programme.
該機構表示,這一評級反映了母公司Sunway Healthcare Holdings Sdn Bhd(SHH)的信用實力,基於SHH對該計劃的無條件和不可撤銷的擔保。
The affirmed rating reflects SHH's strengthening business profile with a growing market share in the Malaysian healthcare sector and strong debt service ability given its robust internal cash flow generation. SHH's healthy liquidity position and strong financial flexibility supported by a strong ownership profile are also key rating factors. These factors are tempered by execution risk associated with the group's rapid expansion plans, its exposure to regulatory and contingent liabilities, and concerns over the industry-wide shortage of nurses.
確認的評級反映了SHH日益增強的業務形象,在馬來西亞醫療行業中市場份額不斷增長,且考慮到其強勁的內部現金流生成能力,債務服務能力強。SHH良好的流動性和強大的財務靈活性,以及強大的所有權結構,也是評級的重要因素。這些因素受到與集團快速擴張計劃相關的執行風險、對監管和或有負債的暴露以及對行業普遍缺乏護士的擔憂的制約。
The group has strengthened its position as a key player in the domestic private healthcare industry. As of September 2024, SHH operates three hospitals with 1,240 licensed beds (end-2023: 1,148 beds), capturing an estimated 7% of the market based on bed count. With two new hospitals opening from 4Q2024 and ongoing expansions, total bed capacity is expected to increase to around 1,900. This, along with strong industry growth drivers, will provide further upside to the group's operational and financial profiles. As of July 2024, SHH's patient throughput reached 741,000 and is on track to surpass the 1.2 million visits recorded in 2023.
該集團已經鞏固了自己作爲國內私人醫療行業關鍵參與者的地位。截至2024年9月,SHH運營着三家醫院,擁有1,240張獲得許可的病牀(2023年年底:1,148張),根據牀位數量佔據約7%的市場份額。隨着兩家新醫院在2024年第四季度開業及正在進行的擴張,總牀位容量預計將增加到約1,900張。再加上強勁的行業增長驅動力,將進一步提升集團的運營和財務形象。截至2024年7月,SHH的患者流量達到741,000,預計將超過2023年錄得的120萬次訪問。
Revenue for 2024 is likely to chart higher than the RM1.5 billion posted in 2023 based on strong 9M2024 results. The solid top-line performance has supported EBITDA growth and strong cash generation. The group projects to generate RM480 million to RM1.2 billion of annual cash flow from operations between 2025 and 2030, supported by portfolio growth.
2024年的營業收入預計將高於2023年的15億馬幣,基於2024年前三季度強勁的業績。穩健的頂線表現支持了EBITDA的增長和強勁的現金生成。該集團預計在2025年至2030年間每年從運營中產生48000萬至12億馬幣的現金流,支持組合的增長。
As at end-September 2024, SHH's borrowings stood at RM1.3 billion, with a debt-to-equity ratio of 0.45x. This is expected to decline slightly by year end to about RM1.0 billion following a scheduled debt repayment of approximately RM282 million. SHH forecasts borrowings in the range of between RM1.1 billion and RM1.7 billion from FY2025 to FY2030, with proceeds primarily funding the group's ongoing expansion plans. MARC Ratings believes the group's cash-generative operations will support the higher debt levels. Under the rating agency's sensitised case, which includes profitability stress, cash flow coverage on interest and debt is expected to remain strong at 7.9x-12.2x and 0.3x-0.4x over the forecast period.
截至2024年9月底,SHH的借款爲13億馬幣,債務與股本比率爲0.45x。預計到年底略微下降至約10億馬幣,原因是計劃還款約爲28200萬馬幣。SHH預測2025至2030財年間的借款區間爲11億至17億馬幣,資金主要用於支持集團持續的擴張計劃。MARC評級認爲,該集團現金生成的運營將支持更高的債務水平。在評級機構的敏感情形下,包括盈利能力壓力,利息和債務的現金流覆蓋預計在預測期內維持在7.9x-12.2x和0.3x-0.4x。
譯文內容由第三人軟體翻譯。